Tirzepatide's additional GIP activation has not introduced new safety concerns in clinical trials, though some patients report slightly different side effect profilesfor instance, slightly more nausea during initial titration but faster resolution
J Biol Chem 270:2648826496 Sharma D, Verma S, Vaidya S, Kalia K, Tiwari V (2018) Recent updates on GLP-1 agonists: current advancements & challenges
However, immune checkpoint monotherapy, mainly blockade of the programmed death ligand 1 (PD-L1) and programmed death 1 (PD-1) pathways, has yielded modest response rates [3], highlighting the need for more effective strategies
Prescribing decisions for older patients must be individualised, considering factors such as frailty, comorbidities, nutritional status, and potential benefits versus risks